We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Trial Data Prompts Novartis, Schering to Rethink Filing Strategy for PTK/ZK
Trial Data Prompts Novartis, Schering to Rethink Filing Strategy for PTK/ZK
July 28, 2005
Novartis and Schering AG are reevaluating the filing strategy for their experimental cancer treatment PTK/ZK after preliminary data from a Phase III trial showed the drug probably won’t extend patients’ lives.